An exploratory study on CLU, CR1 and PICALM and Parkinson disease

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Gao, Jianjun ^a   Huang, Xuemei ^b   Park, YikYung ^c   Hollenbeck, Albert ^d   Chen, Honglei ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d AARP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; CLATHRIN ASSEMBLY PROTEIN; CLUSTERIN; COMPLEMENT COMPONENT C3B RECEPTOR; CR1 PROTEIN, HUMAN; PICALM PROTEIN, HUMAN;

AGED; ARTICLE; BIRTH; CAFFEINE INTAKE; CASE CONTROL STUDY; CLU GENE; COHORT ANALYSIS; CONTROLLED STUDY; CR1 GENE; DEMENTIA; DIETARY INTAKE; DISEASE ASSOCIATION; DNA EXTRACTION; ETHNICITY; FAMILY HISTORY; FEMALE; GENDER; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PICALM GENE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; YEAR OF BIRTH; GENETICS;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CLUSTERIN; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MONOMERIC CLATHRIN ASSEMBLY PROTEINS; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, COMPLEMENT 3B;

EID: 80052284860     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024211     Document Type: Article

References (34)

1. Ross CA, Poirier MA, (2004) Protein aggregation and neurodegenerative disease. Nat Med 10 (Suppl): S10-17.
2. Caballol N, Marti MJ, Tolosa E, (2007) Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 22 (Suppl 17): S358-366.
3. Wilson RS, Bennett DA, Gilley DW, Beckett LA, Schneider JA, et al. (2000) Progression of parkinsonian signs in Alzheimer's disease. Neurology 54: 1284-1289.
4. Levy G, Louis ED, Mejia-Santana H, Cote L, Andrews H, et al. (2004) Lack of familial aggregation of Parkinson disease and Alzheimer disease. Arch Neurol 61: 1033-1039.
5. Hofman A, Schulte W, Tanja TA, van Duijn CM, Haaxma R, et al. (1989) History of dementia and Parkinson's disease in 1st-degree relatives of patients with Alzheimer's disease. Neurology 39: 1589-1592.
6. Costello S, Bordelon Y, Bronstein J, Ritz B, (2010) Familial associations of Alzheimer disease and essential tremor with Parkinson disease. Eur J Neurol 17: 871-878.
7. Rosen AR, Steenland NK, Hanfelt J, Factor SA, Lah JJ, et al. (2007) Evidence of shared risk for Alzheimer's disease and Parkinson's disease using family history. Neurogenetics 8: 263-270.
8. Marder K, Tang MX, Alfaro B, Mejia H, Cote L, et al. (1999) Risk of Alzheimer's disease in relatives of Parkinson's disease patients with and without dementia. Neurology 52: 719-724.
9. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41: 1088-1093.
10. Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41: 1094-1099.
11. Jun G, Naj AC, Beecham GW, Wang LS, Buros J, et al. (2010) Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol 67: 1473-1484.
12. Hughes AJ, Daniel SE, Lees AJ, (1993) The clinical features of Parkinson's disease in 100 histologically proven cases. Adv Neurol 60: 595-599.
13. Huang X, Chen PC, Poole C, (2004) APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology 62: 2198-2202.
14. Williams-Gray CH, Goris A, Saiki M, Foltynie T, Compston DA, et al. (2009) Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol 256: 493-498.
15. Blazquez L, Otaegui D, Saenz A, Paisan-Ruiz C, Emparanza JI, et al. (2006) Apolipoprotein E epsilon4 allele in familial and sporadic Parkinson's disease. Neurosci Lett 406: 235-239.
16. Ghebremedhin E, Del Tredici K, Vuksic M, Rub U, Thal DR, et al. (2006) Relationship of apolipoprotein E and age at onset to Parkinson disease neuropathology. J Neuropathol Exp Neurol 65: 116-123.
17. Group TFPsDGS (1997) Apolipoprotein E genotype in familial Parkinson's disease. The French Parkinson's Disease Genetics Study Group. J Neurol Neurosurg Psychiatry 63: 394-395.
18. Papapetropoulos S, Farrer MJ, Stone JT, Milkovic NM, Ross OA, et al. (2007) Phenotypic associations of tau and ApoE in Parkinson's disease. Neurosci Lett 414: 141-144.
19. Gao JJ, Huang XM, Park Y, Liu R, Hollenbeck A, et al. Apolipoprotein E genotypes and the risk of Parkinson disease. Neurobiol Aging (In press).
20. Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW, (2008) Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov Disord 23: 1013-1018.
21. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM, (2006) Serum cholesterol levels and the risk of Parkinson's disease. Am J Epidemiol 164: 998-1002.
22. Simon KC, Chen H, Schwarzschild M, Ascherio A, (2007) Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 69: 1688-1695.
23. Nuutinen T, Suuronen T, Kauppinen A, Salminen A, (2009) Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 61: 89-104.
24. Sleegers K, Lambert JC, Bertram L, Cruts M, Amouyel P, et al. (2010) The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet 26: 84-93.
25. Sasaki K, Doh-ura K, Wakisaka Y, Iwaki T, (2002) Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies. Acta Neuropathol 104: 225-230.
26. Carreras I, Garrett-Young R, Ullman MD, Eisenhauer PB, Fine RE, et al. (2005) Upregulation of clusterin/apolipoprotein J in lactacystin-treated SH-SY5Y cells. J Neurosci Res 79: 495-502.
27. Prikrylova Vranova H, Mares J, Nevrly M, Stejskal D, Zapletalova J, et al. (2010) CSF markers of neurodegeneration in Parkinson's disease. J Neural Transm 117: 1177-1181.
28. Hughes AJ, Daniel SE, Lees AJ, (2001) Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 57: 1497-1499.
29. Schatzkin A, Subar AF, Thompson FE, Harlan LC, Tangrea J, et al. (2001) Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol 154: 1119-1125.
30. Chen H, Huang X, Guo X, Mailman RB, Park Y, et al. (2010) Smoking duration, intensity, and risk of Parkinson disease. Neurology 74: 878-884.
31. Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, et al. (2001) Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 50: 56-63.
32. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, et al. (2005) Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 58: 963-967.
33. Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A, (2002) Diet and Parkinson's disease: a potential role of dairy products in men. Ann Neurol 52: 793-801.
34. Gauderman W, Morrison J, (2006) QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies,http://hydra.usc.edu/gxe.